Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas

Modern Pathology

Volumn 24, Issue 11, 2011, Pages 1511-1520

  Toubaji, Antoun ^a   Albadine, Roula ^a   Meeker, Alan K ^a,b   Isaacs, William B ^b,c   Lotan, Tamara ^a   Haffner, Michael C ^a,c   Chaux, Alcides ^a   Epstein, Jonathan I ^a,b,c   Han, Misop ^b   Walsh, Patrick C ^b,c   Partin, Alan W ^b,c   De Marzo, Angelo M ^a,b,c   Platz, Elizabeth A ^b,c,d   Netto, George J ^a,b,c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

fluorescence in situ hybridization; nested case control study; prognosis; prostate adenocarcinoma; TMPRSS2 ERG fusion

Indexed keywords

HYBRID PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ERG TMPRSS2 FUSION PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CHROMOSOME 21; CONTROLLED STUDY; ETHNICITY; GENE DOSAGE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RACE; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; BALTIMORE; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 21; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; ONCOGENE PROTEINS, FUSION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TREATMENT OUTCOME;

EID: 80455174007     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.111     Document Type: Article

References (40)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
2. Andriole GL, Crawford ED, Grubb III RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319.
3. Wang J, Cai Y, Yu W, et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008;68:8516-8524.
4. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826-832. (Pubitemid 44564838)
5. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-888. (Pubitemid 47165141)
6. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243. (Pubitemid 350084545)
7. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544. (Pubitemid 46631996)
8. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007;20:467-473. (Pubitemid 46482370)
9. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26: 4596-4599. (Pubitemid 47037039)
10. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-45. (Pubitemid 46294173)
11. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263.
12. Cheville JC, Karnes RJ, Therneau TM, et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008;26:3930-3936.
13. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-1406.
14. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adeno-carcinomas. Mod Pathol 2009;22:359-365.
15. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009;22:1415-1422.
16. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006;66: 10658-10663. (Pubitemid 44876959)
17. Rubio-Briones J, Fernandez-Serra A, Calatrava A, et al. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol 2010;183: 2054-2061.
18. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565. (Pubitemid 32916759)
19. Wang MH, Shugart YY, Cole SR, et al. A simulation study of control sampling methods for nested case-control studies of genetic and molecular biomarkers and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 2009;18:706-711.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847. (Pubitemid 28331029)
21. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695. (Pubitemid 350249347)
22. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008;68:3584-3590.
23. Hermans KG, Boormans JL, Gasi D, et al. Overexpres-sion of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-6403.
24. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-469. (Pubitemid 44035330)
25. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101:811-816. (Pubitemid 38121040)
26. Rouzier C, Haudebourg J, Carpentier X, et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet 2008;183:21-27. (Pubitemid 351636124)
27. Barwick BG, Abramovitz M, Kodani M, et al. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 2010;102:570-576.
28. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008;14:3395-3400.
29. Bismar TA, Trpkov K. TMPRSS2-ERG gene fusion in transition zone prostate cancer. Mod Pathol 2010;23: 1040-1041.
30. Liu S, Yoshimoto M, Trpkov K, et al. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther 2011;11:562-566.
31. Falzarano SM, Navas M, Simmerman K, et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 2010;23:1499-1506.
32. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007;20:921-928. (Pubitemid 47267823)
33. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75. (Pubitemid 351172158)
34. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008;27:1993-2003. (Pubitemid 351442741)
35. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007;26:2667-2673. (Pubitemid 46632014)
36. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216: 34-63.
37. Brown JA, Slezak JM, Lieber MM, et al. Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy. Mayo Clin Proc 1999;74:1214-1220.
38. Lau WK, Blute ML, Bostwick DG, et al. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 2001;166:1692-1697.
39. Barry M, Perner S, Demichelis F, et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70: 630-633. (Pubitemid 350030260)
40. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67:7991-7995. (Pubitemid 47395131)